Compounds > 2,6-di-tert-butyl-4-hydroxy-4-methyl-2,5-cyclohexadien-1-one
Page last updated: 2024-11-07

2,6-di-tert-butyl-4-hydroxy-4-methyl-2,5-cyclohexadien-1-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID146102
SCHEMBL ID7213737
MeSH IDM0116208

Synonyms (33)

Synonym
2,5-cyclohexadien-1-one,2,6-bis(1,1-dimethylethyl)-4-hydroxy-4-methyl-
2,6-di(t-butyl)-4-hydroxy-4-methyl-2,5-cyclohexadien-1-one
2,6-di(t-butyl)-4-hydroxy-4-methyl-2,5-cyclohexadiene-1-one
2,6-di-t-butyl-4-hydroxy-4-methyl-2,5-cyclohexadienone
2,5-cyclohexadien-1-one, 2,6-di-tert-butyl-4-hydroxy-4-methyl-
2,6-di-tert-butyl-4-hydroxy-4-methyl-2,5-cyclohexadien-1-one
brn 2050856
bht-oh
c15h24o2
dqbhjilnhnrdtm-uhfffaoysa-
inchi=1/c15h24o2/c1-13(2,3)10-8-15(7,17)9-11(12(10)16)14(4,5)6/h8-9,17h,1-7h3
2,6-ditert-butyl-4-hydroxy-4-methylcyclohexa-2,5-dien-1-one
2,6-di(tert-butyl)-4-hydroxy-4-methyl-2,5-cyclohexadien-1-one
10396-80-2
unii-rck267mps5
4-08-00-00142 (beilstein handbook reference)
rck267mps5 ,
AB09882
2,5-cyclohexadien-1-one, 2,6-bis(1,1-dimethylethyl)-4-hydroxy-4-methyl-
2,6-di-tert-butyl-4-hydroxy-4-methyl-2,5-cyclohexadienone
4-hydroxy-4-methyl-2,6-di-tert-butyl-2,5-cyclohexadienone
4-methyl-4-hydroxy-2,6-di-t-butylcyclohexa-2,5-diene-1-one
SCHEMBL7213737
2,6-di-tert-butyl-4-hydroxy-4-methylcyclohexa-2,5-dien-1-one
DTXSID10146165
J-001078
2,6-di-tert-butyl-4-hydroxy-4-methylcyclohexa-2,5-dienone
mfcd01734499
AT10109
Q27288051
BS-25552
CS-0440337
EN300-6503846

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"-butyl-4-[alpha, alpha, alpha-2H3]methylphenol (BHT-d3) showed a significantly lower toxic potency of the latter."( Isotope effects on the metabolism and pulmonary toxicity of butylated hydroxytoluene in mice by deuteration of the 4-methyl group.
Mizutani, T; Tajima, K; Yamamoto, K, 1983)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's2 (28.57)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.54 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydroquinone
[no description available]		2.610benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
2,6-di-tert-butyl-4-hydroxymethylphenol
2,6-di-tert-butyl-4-hydroxymethylphenol: structure given in first source		1.9810alkylbenzene
3,5-di-tert-butyl-4-hydroxybenzoic acid
[no description available]		2.610
2-tert-butylhydroquinone
2-tert-butylhydroquinone: an anticarcinogenic and chemopreventive agent. 2-tert-butylhydroquinone : A member of the class of hydroquinones in which one of the ring hydrogens of hydroquinone is replaced by a tert-butyl group.		2.610hydroquinonesfood antioxidant
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		1.9610dihydrogen
tiletamine hydrochloride
Cyclohexanones: Cyclohexane ring substituted by one or more ketones in any position.. cyclohexanones : Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.		1.9610
tetradecanoylphorbol acetate
Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.		1.9810acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
3,5-di-tert-butyl-4-hydroxybenzaldehyde
3,5-di-tert-butyl-4-hydroxybenzaldehyde: structure in first source		2.6120hydroxybenzaldehyde
2,6-di-tert-butyl-4-methylene-2,5-cyclohexadienone
2,6-di-tert-butyl-4-methylene-2,5-cyclohexadienone: metabolite of butylated hydroxytoluene; structure given in first source		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Lung
[description not available]		02.4120
Lung Neoplasms
Tumors or cancer of the LUNG.		02.4120
Disease, Pulmonary
[description not available]		01.9610
Lung Diseases
Pathological processes involving any part of the LUNG.		01.9610
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		01.9910